Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan B Sandler

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Clinical Lung Cancer|March 24, 2012
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancerGiorgio V Scagliotti, Silvia Novello, Joan H Schiller, et al.
The Oncologist|March 28, 2025
Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancerMitchell S von Itzstein, Sawsan Rashdan, Suzanne E Dahlberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinomaMark G Kris, Giuseppe Giaccone, Angela Davies, et al.
Cancer Chemotherapy and Pharmacology|May 21, 2005
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumorsHiroyuki Kobayashi, S Gail Eckhardt, Jennifer A Lockridge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapyJohan Vansteenkiste, Primo N Lara, Thierry Le Chevalier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group BDavid M Dilts, Alan B Sandler, Matthew Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2005
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732Harvey B Niell, James E Herndon, Antonius A Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinibVincent A Miller, Gregory J Riely, Maureen F Zakowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancerJohn V Heymach, Luis Paz-Ares, Filippo De Braud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 3, 2008
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancerMary E R O'Brien, Mark A Socinski, Alexander Y Popovich, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Clinical Lung Cancer|March 24, 2012
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancerGiorgio V Scagliotti, Silvia Novello, Joan H Schiller, et al.
The Oncologist|March 28, 2025
Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancerMitchell S von Itzstein, Sawsan Rashdan, Suzanne E Dahlberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinomaMark G Kris, Giuseppe Giaccone, Angela Davies, et al.
Cancer Chemotherapy and Pharmacology|May 21, 2005
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumorsHiroyuki Kobayashi, S Gail Eckhardt, Jennifer A Lockridge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapyJohan Vansteenkiste, Primo N Lara, Thierry Le Chevalier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group BDavid M Dilts, Alan B Sandler, Matthew Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2005
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732Harvey B Niell, James E Herndon, Antonius A Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinibVincent A Miller, Gregory J Riely, Maureen F Zakowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancerJohn V Heymach, Luis Paz-Ares, Filippo De Braud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 3, 2008
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancerMary E R O'Brien, Mark A Socinski, Alexander Y Popovich, et al.
Pageof 7